Cargando…

PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Valentin Hansen, Simone, Koldby Blum, Mia, Høy Hansen, Marcus, Cédile, Oriane, Haaber, Jacob, Abildgaard, Niels, Guldborg Nyvold, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429708/ http://dx.doi.org/10.1097/01.HS9.0000976288.25523.df

Ejemplares similares

PB2386: ASSESSMENT OF NANOPORE LONG-READ WHOLE-GENOME SEQUENCING FOR THE DETECTION OF LARGE CHROMOSOMAL STRUCTURAL VARIANTS IN MANTLE CELL LYMPHOMA
por: Hansen, Marcus, et al.
Publicado: (2023)

Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4
por: Valentin Hansen, Simone, et al.
Publicado: (2021)

PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022)

Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing
por: Elkjær, Lea Amalia Lind, et al.
Publicado: (2022)

Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma
por: Hansen, Marcus Høy, et al.
Publicado: (2021)

Replicate whole-genome next-generation sequencing data derived from Caucasian donor saliva samples
por: Hansen, Marcus Høy, et al.
Publicado: (2021)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

Harnessing the Immune System to Fight Multiple Myeloma
por: Krejcik, Jakub, et al.
Publicado: (2021)

PTPRJ Inhibits Leptin Signaling, and Induction of PTPRJ in the Hypothalamus Is a Cause of the Development of Leptin Resistance
por: Shintani, Takafumi, et al.
Publicado: (2017)

PB2077: POD12 AND POD24 – A NEW SURROGATE MARKER IN MANTLE CELL LYMPHOMA TREATMENT?
por: Freitas, J., et al.
Publicado: (2022)

PB2082: POPULATION-WIDE PATTERNS OF CARE IN MANTLE CELL LYMPHOMA IN AUSTRALIA: AN ANALYSIS OF THE PHARMACEUTICAL BENEFITS SCHEME DATASET
por: Tam, C., et al.
Publicado: (2022)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

PB2384: EVALUATION OF NEW MACHINE LEARNING SYSTEMS FOR PROGNOSTICATION BASED ON GENE EXPRESSION SIGNATURES IN MANTLE CELL AND PERIPHERAL T CELL LYMPHOMAS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

2394. Comparative Analysis of Behavior Change and Vaccine Uptake Beliefs
por: Walsh, Tyler, et al.
Publicado: (2023)

PB2268: PAX5 ABERRANT EXPRESSION INCORPORATED IN MIPI-SP RISK SCORING SYSTEM EXHIBITS ADDITIVE VALUE IN MANTLE CELL LYMPHOMA
por: Zhang, Xin, et al.
Publicado: (2023)

Novel scripts for improved annotation and selection of variants from whole exome sequencing in cancer research
por: Hansen, Marcus Celik, et al.
Publicado: (2015)

PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
por: Naylor, G. U., et al.
Publicado: (2022)

PB2229: NECESSITY FOR A ROBUST INFRASTRUCTURE FOR TREATING ALLIED COMPLICATIONS OF AGEING HAEMOGLOBINOPATHY POPULATION IN MIDDLE INCOME COUNTRIES
por: Imran, T., et al.
Publicado: (2022)

PB2174: ON THE ROBUSTNESS OF THE BUCCAL EPITHELIUM FOR ASSESSING RECIPIENT DNA PROFILE IN PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Risinskaya, N., et al.
Publicado: (2022)

PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023)

2394. A Longitudinal Study of the Effect of Renal Failure on Readmission Rates of Patients with Clostridioides difficile
por: Destache, Christopher J, et al.
Publicado: (2019)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

Regulated Expression of PTPRJ by COX-2/PGE(2) Axis in Endothelial Cells
por: Xu, Xiaobing, et al.
Publicado: (2014)

PB2120: HIV AND MALIGNANT HEMOPATHIES
por: Khibri, H., et al.
Publicado: (2022)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
por: Linton, Kim, et al.
Publicado: (2023)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
por: Kapsouli, F., et al.
Publicado: (2022)

PB2322: TTP AFTER COVID 19
por: Gagloeva, D., et al.
Publicado: (2022)

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB2363: REPORTING LANGUAGE IN HAEMATOLOGICAL MALIGNANCIES
por: Watt, S., et al.
Publicado: (2022)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB2601: BLOOD POLLUTION IN THE AGE OF NANO
por: Rolli, Marco
Publicado: (2023)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

PB2633: HEMOSTASIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS
por: Musayeva, Nargiza, et al.
Publicado: (2023)

PB2658: IMMUNE THROMBOCYTOPENIC PURPURA IN ALBANIA
por: Grazhdani, Sara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h4v35kilqqkr144e6aendbmhmh